원내감염증 검사 시장 : 세계 산업 규모, 점유율, 동향, 기회, 예측 - 검사 유형별, 감염 유형별, 제품별, 유형별, 지역별, 경쟁(2021-2031년)
Hospital Acquired Disease Testing Market - Global Industry Size, Share, Trends, Opportunity, & Forecast Segmented By Test Type, By Infection Type, By Product, By Type, By Region & Competition, 2021-2031F
상품코드:1961158
리서치사:TechSci Research
발행일:2026년 01월
페이지 정보:영문 180 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
한글목차
세계의 원내감염 검사 시장은 2025년 52억 9,000만 달러에서 2031년까지 83억 4,000만 달러로 확대하며, CAGR 7.88%로 현저한 성장이 전망되고 있습니다.
본 시장은 의료 환경 내에서 환자에게 전파되는 바이러스, 세균 등 감염성 병원체를 검출하기 위한 각종 스크리닝 절차 및 진단 검사를 포괄하고 있습니다. 이러한 성장을 가속화하는 주요 요인으로는 병원내 감염 발생률 증가, 이러한 질병에 매우 취약한 고령 인구 증가, 감염 관리에 대한 정부의 엄격한 의무화, 항균제 적정 사용 프로그램의 도입이 필수적이라는 점을 꼽을 수 있습니다.
시장 개요
예측 기간
2027-2031년
시장 규모 : 2025년
52억 9,000만 달러
시장 규모 : 2031년
83억 4,000만 달러
CAGR : 2026-2031년
7.88%
가장 빠르게 성장하는 부문
분자 검사
최대 시장
유럽
이러한 성장 요인에도 불구하고 시장은 고급 분자진단과 관련된 높은 비용이라는 큰 장벽에 직면해 있으며, 이는 자원이 한정된 지역에서의 도입을 제한하고 있습니다. 그러나 내성 병원균의 심각한 부담을 고려할 때 이러한 검사 솔루션에 대한 수요는 여전히 높습니다. 세계보건기구(WHO)의 데이터는 이러한 긴급성을 강조하고 있으며, 2024년까지 전 세계에서 약 13억 6천만 건의 항생제 내성 의료 관련 감염이 발생할 것으로 추정되며, 효과적인 진단적 개입의 필요성이 매우 중요하다는 것을 보여줍니다.
시장 성장 촉진요인
신속 진단 기술의 발전은 보다 빠르고 정밀한 병원체 검출을 가능하게 함으로써 전 세계 병원내 감염 검사 시장을 근본적으로 변화시키고 있습니다. 기존의 배양법에서 첨단 분자진단 기술, 특히 증후군 검사로 전환하면서 의료진은 며칠이 아닌 몇 시간 만에 여러 감염 병원체를 식별할 수 있게 되었습니다. 이는 항균제 치료의 신속한 시작과 환자 결과 개선에 매우 중요합니다. 이러한 혁신 기술의 상업적 실현 가능성은 채택 확대에서 분명하게 드러나고 있습니다. 예를 들어 바이오매트리얼유는 2024년 9월 발표한 '2024년 상반기 실적 보고'에서 수막염, 패혈증 등 진단에 필수적인 비호흡기계 패널 '바이오파이어'의 유기적 매출이 19% 증가했다고 보고했습니다.
동시에, 다제내성 병원균의 위협이 심각해짐에 따라 의료시설이 슈퍼박테리아에 대응하기 위해 고군분투하고 있는 상황에서 이러한 첨단 검사 솔루션의 필요성이 더욱 커지고 있습니다. 내성 메커니즘이 진화하고 표준 항생제의 효과가 감소하는 가운데, 항균제의 올바른 사용 지침 수립과 감염 확산 방지를 위해 정밀한 진단이 필수적입니다. 이러한 시급성은 장기적인 예측에서도 강조되고 있습니다. 웰컴 재단의 2024년 9월 보고서에 따르면 2025-2050년까지 항생제 내성 감염으로 인한 사망자 수가 3,900만 명 이상에 달할 것으로 예측됩니다. 또한 미국 질병예방통제센터(CDC)는 2024년 7월, 다제내성 진균인 칸디다 아우리스(Candida auris)의 임상 사례 보고가 2019년 이후 약 5배 증가했다고 발표했습니다.
시장이 해결해야 할 과제
첨단 분자진단과 관련된 높은 비용은 세계 병원내 감염 검사 시장의 성장에 큰 장벽으로 작용하고 있습니다. 의료시설, 특히 자원이 한정된 환경의 의료시설에서는 최첨단 검사 툴의 도입과 필수 운영 비용의 균형을 맞추는 데 있으며, 어려운 결정을 내려야 하는 경우가 많습니다. 그 결과, 정확하지만 비용이 많이 드는 분자 검사 방법의 도입이 제한되는 경우가 많으며, 많은 의료 서비스 프로바이더는 기존의 저렴한 진단 방법에 의존할 수밖에 없어 필요한 치료 및 감염 관리 프로토콜을 지연시킬 수 있습니다.
이러한 재정적 제약은 전체 의료비에서 진단기술에 대한 투자가 차지하는 비중이 상대적으로 낮다는 점에서도 나타납니다. 검사에 대한 예산 배분이 다른 의료 분야에 비해 불균형적으로 적은 상태가 지속되면 시장 확대가 저해됩니다. MedTech Europe에 따르면 2024년 체외진단 의약품에 대한 지출은 전체 헬스케어 지출의 0.6%에 불과할 것으로 추정됩니다. 이 통계는 첨단 검사 솔루션의 도입을 방해하는 심각한 예산 제약으로 인해 시장이 전염병 확산으로 인한 수요에 완전히 대응하지 못하고 있음을 보여줍니다.
시장 동향
현장 검사(POC) 검사의 확대로 병원내 감염성 질환의 검출이 분산되어 의료진은 센트럴 랩의 결과를 기다릴 필요 없이 병상에서 직접 병원균을 확인할 수 있게 되었습니다. 이번 전환으로 검사 결과 반환 시간이 크게 단축되어 감염 발생시 격리 및 치료 방침을 즉각적으로 결정할 수 있게 되었으며, 특히 감염 위험이 높은 병동에서 감염 확산 방지에 매우 중요한 역할을 합니다. 이러한 추세가 시장에 미치는 영향은 분산형 분자 플랫폼의 빠른 상업적 보급으로 두드러지게 나타나고 있습니다. 예를 들어 바이오메트류는 2025년 3월, 의료시설의 도입 기반 확대에 힘입어 SPOTFIRE Point-of-Care 솔루션의 연간 매출액이 9,500만 유로에 달했다고 보고했습니다.
동시에 헬스케어 네트워크 전반의 감염률과 항균제 내성 패턴을 모니터링하는 실시간 디지털 모니터링 시스템으로의 전환이 눈에 띄게 진행되고 있습니다. 이 시스템은 입원 환자 데이터와 수술 데이터를 통합하여 고위험 영역을 식별하고 감염 관리 기준 준수를 보장하여 관리자를 위한 지속적인 피드백 루프를 구축합니다. 이러한 감시 프로그램 참여가 정기적인 검사 수요를 촉진하고 있으며, 영국 보건안전청(UK Health Security Agency)의 2025년 12월 보고서에 따르면 감시 분석 대상으로 제출된 수술 건수는 전년 대비 7.9% 증가했습니다. 모니터링 의무 준수 강화가 반영되어 있습니다.
목차
제1장 개요
제2장 조사 방법
제3장 개요
제4장 고객의 소리
제5장 세계의 원내감염증 검사 시장 전망
제6장 북미의 원내감염증 검사 시장 전망
제7장 유럽의 원내감염증 검사 시장 전망
제8장 아시아태평양의 원내감염증 검사 시장 전망
제9장 중동 및 아프리카의 원내감염증 검사 시장 전망
제10장 남미의 원내감염증 검사 시장 전망
제11장 시장 역학
제12장 시장 동향과 발전
제13장 세계의 원내감염증 검사 시장 : SWOT 분석
제14장 Porter's Five Forces 분석
제15장 경쟁 구도
제16장 전략적 제안
제17장 조사회사 소개·면책사항
KSA
영문 목차
영문목차
The Global Hospital Acquired Disease Testing Market is projected to experience significant growth, expanding from USD 5.29 Billion in 2025 to USD 8.34 Billion by 2031, reflecting a CAGR of 7.88%. This market encompasses various screening procedures and diagnostic assays intended to detect infectious agents, including viruses and bacteria, that are transmitted to patients within medical environments. Key drivers accelerating this growth include the increasing incidence of nosocomial infections and a growing geriatric demographic that is highly vulnerable to such conditions, alongside strict government mandates for infection control and the essential adoption of antimicrobial stewardship programs.
Market Overview
Forecast Period
2027-2031
Market Size 2025
USD 5.29 Billion
Market Size 2031
USD 8.34 Billion
CAGR 2026-2031
7.88%
Fastest Growing Segment
Molecular Tests
Largest Market
Europe
Despite these growth factors, the market faces a substantial obstacle in the form of high costs linked to advanced molecular diagnostics, which restricts their deployment in regions with limited resources. Nevertheless, the demand for these testing solutions remains acute given the heavy burden of resistant pathogens. Data from the World Health Organization underscores this urgency, estimating that in 2024, approximately 136 million antibiotic-resistant healthcare-associated infections occurred globally, highlighting the critical need for effective diagnostic interventions.
Market Driver
Advancements in rapid diagnostic technologies are fundamentally transforming the Global Hospital Acquired Disease Testing Market by facilitating earlier and more precise pathogen detection. The shift from conventional culture-based techniques to sophisticated molecular diagnostics, particularly syndromic testing, enables medical professionals to identify multiple infectious agents in hours instead of days, which is crucial for timely antimicrobial therapy and improved patient outcomes. The commercial viability of these innovations is evident in their increasing adoption; for example, bioMerieux reported in their 'First-Half 2024 Financial Results' in September 2024 that organic sales of their BIOFIRE non-respiratory panels, essential for diagnosing conditions like meningitis and sepsis, rose by 19%.
At the same time, the escalating threat of multidrug-resistant pathogens is driving the necessity for these advanced testing solutions as healthcare facilities fight to control superbugs. As resistance mechanisms evolve and standard antibiotics become less effective, precise diagnostics are essential for guiding antimicrobial stewardship and preventing outbreaks. This urgency is emphasized by long-term forecasts; a September 2024 report by Wellcome predicts over 39 million deaths will be attributed to antibiotic-resistant infections between 2025 and 2050, while the Centers for Disease Control and Prevention noted in July 2024 that reported clinical cases of the multidrug-resistant fungus Candida auris increased nearly five-fold since 2019.
Market Challenge
The substantial expense associated with advanced molecular diagnostics poses a significant barrier to the growth of the Global Hospital Acquired Disease Testing Market. Healthcare institutions, particularly those in resource-limited settings, often face difficult decisions when balancing the acquisition of cutting-edge screening tools against essential operational costs. Consequently, the adoption of precise yet costly molecular assays is often limited, compelling many providers to depend on traditional, less expensive diagnostic methods that may delay necessary treatment and infection control protocols.
This financial constraint is further illustrated by the relatively low investment in diagnostic technologies compared to overall healthcare spending. Market expansion is stifled when budgetary allocations for testing remain disproportionately small relative to other medical verticals. According to MedTech Europe, expenditure on in vitro diagnostics in 2024 was estimated to account for only 0.6% of total healthcare spending. This statistic underscores the severe budgetary limitations that hinder the uptake of advanced testing solutions, preventing the market from fully addressing the demand generated by the prevalence of infectious diseases.
Market Trends
The expansion of Point-of-Care (POC) testing is decentralizing the detection of hospital-acquired diseases, enabling healthcare providers to identify pathogens directly at the bedside rather than waiting for central laboratory results. This transition significantly lowers turnaround times, allowing for immediate isolation and treatment decisions that are vital for containing outbreaks in sensitive wards. The market impact of this trend is highlighted by the swift commercial adoption of decentralized molecular platforms; for instance, bioMerieux reported in March 2025 that sales of its SPOTFIRE point-of-care solution reached €95 million for the year, driven by a growing installed base across medical facilities.
Concurrently, there is a notable shift toward real-time digital surveillance systems designed to monitor infection rates and antimicrobial resistance patterns throughout healthcare networks. These systems compile data from inpatient stays and surgical procedures to pinpoint high-risk areas and ensure compliance with infection control standards, creating a continuous feedback loop for administrators. Participation in these monitoring programs is fueling demand for consistent testing, as evidenced by the UK Health Security Agency's December 2025 report, which noted a 7.9% increase in the volume of surgical procedures submitted for surveillance analysis compared to the previous year, reflecting increased adherence to monitoring mandates.
Key Market Players
bioMerieux SA
Abbott Laboratories Inc.
F. Hoffmann-La Roche Ltd.
Siemens Healthcare Private Limited
Becton, Dickinson and Company
Bioscience, Inc.
QIAGEN N.V.
Thermo Fisher Scientific Inc
Hologic, Inc.
Meridian Bioscience, Inc
Report Scope
In this report, the Global Hospital Acquired Disease Testing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Hospital Acquired Disease Testing Market, By Test Type
Molecular
Conventional
Hospital Acquired Disease Testing Market, By Infection Type
UTI
Pneumonia
Surgical Site Infection
Blood Stream Infections
Others
Hospital Acquired Disease Testing Market, By Product
Consumables
Instruments
Hospital Acquired Disease Testing Market, By Type
Blood Tests
Urinalysis
Hospital Acquired Disease Testing Market, By Region
North America
United States
Canada
Mexico
Europe
France
United Kingdom
Italy
Germany
Spain
Asia Pacific
China
India
Japan
Australia
South Korea
South America
Brazil
Argentina
Colombia
Middle East & Africa
South Africa
Saudi Arabia
UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Hospital Acquired Disease Testing Market.
Available Customizations:
Global Hospital Acquired Disease Testing Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
Detailed analysis and profiling of additional market players (up to five).
Table of Contents
1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Hospital Acquired Disease Testing Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Test Type (Molecular, Conventional)
5.2.2. By Infection Type (UTI, Pneumonia, Surgical Site Infection, Blood Stream Infections, Others)
5.2.3. By Product (Consumables, Instruments)
5.2.4. By Type (Blood Tests, Urinalysis)
5.2.5. By Region
5.2.6. By Company (2025)
5.3. Market Map
6. North America Hospital Acquired Disease Testing Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Test Type
6.2.2. By Infection Type
6.2.3. By Product
6.2.4. By Type
6.2.5. By Country
6.3. North America: Country Analysis
6.3.1. United States Hospital Acquired Disease Testing Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Test Type
6.3.1.2.2. By Infection Type
6.3.1.2.3. By Product
6.3.1.2.4. By Type
6.3.2. Canada Hospital Acquired Disease Testing Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Test Type
6.3.2.2.2. By Infection Type
6.3.2.2.3. By Product
6.3.2.2.4. By Type
6.3.3. Mexico Hospital Acquired Disease Testing Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Test Type
6.3.3.2.2. By Infection Type
6.3.3.2.3. By Product
6.3.3.2.4. By Type
7. Europe Hospital Acquired Disease Testing Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Test Type
7.2.2. By Infection Type
7.2.3. By Product
7.2.4. By Type
7.2.5. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Hospital Acquired Disease Testing Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Test Type
7.3.1.2.2. By Infection Type
7.3.1.2.3. By Product
7.3.1.2.4. By Type
7.3.2. France Hospital Acquired Disease Testing Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Test Type
7.3.2.2.2. By Infection Type
7.3.2.2.3. By Product
7.3.2.2.4. By Type
7.3.3. United Kingdom Hospital Acquired Disease Testing Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Test Type
7.3.3.2.2. By Infection Type
7.3.3.2.3. By Product
7.3.3.2.4. By Type
7.3.4. Italy Hospital Acquired Disease Testing Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Test Type
7.3.4.2.2. By Infection Type
7.3.4.2.3. By Product
7.3.4.2.4. By Type
7.3.5. Spain Hospital Acquired Disease Testing Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Test Type
7.3.5.2.2. By Infection Type
7.3.5.2.3. By Product
7.3.5.2.4. By Type
8. Asia Pacific Hospital Acquired Disease Testing Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Test Type
8.2.2. By Infection Type
8.2.3. By Product
8.2.4. By Type
8.2.5. By Country
8.3. Asia Pacific: Country Analysis
8.3.1. China Hospital Acquired Disease Testing Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Test Type
8.3.1.2.2. By Infection Type
8.3.1.2.3. By Product
8.3.1.2.4. By Type
8.3.2. India Hospital Acquired Disease Testing Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Test Type
8.3.2.2.2. By Infection Type
8.3.2.2.3. By Product
8.3.2.2.4. By Type
8.3.3. Japan Hospital Acquired Disease Testing Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Test Type
8.3.3.2.2. By Infection Type
8.3.3.2.3. By Product
8.3.3.2.4. By Type
8.3.4. South Korea Hospital Acquired Disease Testing Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Test Type
8.3.4.2.2. By Infection Type
8.3.4.2.3. By Product
8.3.4.2.4. By Type
8.3.5. Australia Hospital Acquired Disease Testing Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Test Type
8.3.5.2.2. By Infection Type
8.3.5.2.3. By Product
8.3.5.2.4. By Type
9. Middle East & Africa Hospital Acquired Disease Testing Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Test Type
9.2.2. By Infection Type
9.2.3. By Product
9.2.4. By Type
9.2.5. By Country
9.3. Middle East & Africa: Country Analysis
9.3.1. Saudi Arabia Hospital Acquired Disease Testing Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Test Type
9.3.1.2.2. By Infection Type
9.3.1.2.3. By Product
9.3.1.2.4. By Type
9.3.2. UAE Hospital Acquired Disease Testing Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Test Type
9.3.2.2.2. By Infection Type
9.3.2.2.3. By Product
9.3.2.2.4. By Type
9.3.3. South Africa Hospital Acquired Disease Testing Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Test Type
9.3.3.2.2. By Infection Type
9.3.3.2.3. By Product
9.3.3.2.4. By Type
10. South America Hospital Acquired Disease Testing Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Test Type
10.2.2. By Infection Type
10.2.3. By Product
10.2.4. By Type
10.2.5. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Hospital Acquired Disease Testing Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Test Type
10.3.1.2.2. By Infection Type
10.3.1.2.3. By Product
10.3.1.2.4. By Type
10.3.2. Colombia Hospital Acquired Disease Testing Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Test Type
10.3.2.2.2. By Infection Type
10.3.2.2.3. By Product
10.3.2.2.4. By Type
10.3.3. Argentina Hospital Acquired Disease Testing Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Test Type
10.3.3.2.2. By Infection Type
10.3.3.2.3. By Product
10.3.3.2.4. By Type
11. Market Dynamics
11.1. Drivers
11.2. Challenges
12. Market Trends & Developments
12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments
13. Global Hospital Acquired Disease Testing Market: SWOT Analysis
